Goldman Sachs Group Inc Adaptimmune Therapeutics PLC Transaction History

Goldman Sachs Group Inc

  • $780 Billion
  • Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Adaptimmune Therapeutics PLC stock. As of the latest transaction made, Goldman Sachs Group Inc holds 12,320 shares of ADAP stock, worth $369. This represents 0.0% of its overall portfolio holdings.

Number of Shares
12,320
Holding current value
$369
% of portfolio
0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025
BUY
$0.04 - $0.35 $492 - $4,312
12,320 New
12,320 $1,000
Q1 2025

May 09, 2025
SELL
$0.2 - $0.65 $2 - $7
-11 Reduced 0.07%
16,149 $3,000
Q4 2024

Feb 11, 2025
SELL
$0.54 - $0.95 $36,855 - $64,837
-68,250 Reduced 80.86%
16,160 $8,000
Q3 2024

Nov 14, 2024
BUY
$0.92 - $1.39 $62,827 - $94,924
68,291 Added 423.67%
84,410 $80,000
Q2 2024

Aug 13, 2024
SELL
$0.83 - $1.47 $75,897 - $134,421
-91,443 Reduced 85.01%
16,119 $15,000
Q1 2024

May 15, 2024
BUY
$0.7 - $1.75 $64,108 - $160,270
91,583 Added 573.15%
107,562 $169,000
Q4 2023

Feb 13, 2024
SELL
$0.43 - $0.79 $17,901 - $32,889
-41,632 Reduced 72.26%
15,979 $12,000
Q3 2023

May 14, 2024
BUY
$0.73 - $1.04 $30,391 - $43,297
41,632 Added 260.54%
57,611 $44,000
Q3 2023

Nov 14, 2023
BUY
$0.73 - $1.04 $6,959 - $9,915
9,534 Added 19.83%
57,611 $44,000
Q2 2023

May 14, 2024
BUY
$0.9 - $1.51 $15,598 - $26,171
17,332 Added 56.37%
48,077 $44,000
Q2 2023

Aug 14, 2023
BUY
$0.9 - $1.51 $15,598 - $26,171
17,332 Added 56.37%
48,077 $44,000
Q1 2023

May 14, 2024
SELL
$1.06 - $2.16 $116,763 - $237,932
-110,154 Reduced 78.18%
30,745 $33,000
Q1 2023

May 11, 2023
SELL
$1.06 - $2.16 $116,763 - $237,932
-110,154 Reduced 78.18%
30,745 $33,000
Q4 2022

May 14, 2024
SELL
$1.05 - $2.53 $319,508 - $769,863
-304,294 Reduced 68.35%
140,899 $205,000
Q4 2022

Feb 13, 2023
SELL
$1.05 - $2.53 $319,508 - $769,863
-304,294 Reduced 68.35%
140,899 $205,000
Q3 2022

May 14, 2024
BUY
$1.06 - $2.41 $88,077 - $200,251
83,092 Added 22.95%
445,193 $479,000
Q3 2022

Nov 10, 2022
BUY
$1.06 - $2.41 $88,077 - $200,251
83,092 Added 22.95%
445,193 $476,000
Q2 2022

May 14, 2024
BUY
$1.33 - $2.28 $460,342 - $789,158
346,122 Added 2166.11%
362,101 $616,000
Q2 2022

Aug 15, 2022
BUY
$1.33 - $2.28 $2,902 - $4,974
2,182 Added 0.61%
362,101 $616,000
Q1 2022

May 16, 2022
BUY
$1.73 - $4.06 $88,935 - $208,716
51,408 Added 16.66%
359,919 $741,000
Q4 2021

Feb 14, 2022
SELL
$3.5 - $5.68 $76,534 - $124,204
-21,867 Reduced 6.62%
308,511 $1.16 Million
Q3 2021

Nov 10, 2021
BUY
$3.44 - $6.37 $1.14 Million - $2.1 Million
330,378 New
330,378 $1.71 Million

Others Institutions Holding ADAP

# of Institutions
58
Shares Held
41.8M
Call Options Held
139K
Put Options Held
144K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $4.9M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email